🟡 Preliminary Evidence
Dexcom, Inc., the leading continuous glucose monitoring manufacturer, has notified the FDA of the theft of defective G7 sensor lots that were designated as scrap and intended for destruction. The company discovered the theft during routine quality and accounting reviews conducted in May 2026.
Key takeaways
- Stolen sensors were manufacturing rejects intended for destruction, not approved products
- Dexcom is conducting quality reviews and has notified potentially affected users
- The FDA has issued a safety alert regarding the compromised device security
Dexcom G7 Market Position
Global continuous glucose monitoring market leadership
Source: Company reports, 2026 | Georgian Medical Journal News
Company Discovers Manufacturing Breach
DexCom, Inc. (Nasdaq: DXCM) announced on May 26, 2026, that ongoing quality and accounting reviews revealed the theft of specific G7 sensor lots originally designated as scrap material. According to the company’s FDA notification, these sensors were manufacturing rejects that failed quality control standards and were intended for destruction.
The San Diego-based glucose biosensing leader has initiated comprehensive reviews of its manufacturing and disposal processes following the discovery. This represents a significant breach in the company’s quality assurance protocols, as scrapped medical devices pose potential safety risks when diverted from proper disposal channels.
FDA Issues Safety Alert for Compromised Devices
The Food and Drug Administration has issued a safety alert regarding the stolen Dexcom G7 sensors, warning healthcare providers and patients about potentially compromised devices in circulation. The agency emphasizes that these particular sensor lots never received regulatory approval for patient use.
Healthcare professionals are advised to verify the authenticity and source of G7 sensors before patient application. The device security breach highlights vulnerabilities in medical device disposal protocols that could compromise patient safety if defective products reach clinical settings.
Patient Notification and Risk Assessment
Dexcom has begun notifying potentially affected users who may have received sensors from the compromised lots. The company is working with healthcare providers to identify any patients who may have used the stolen devices and assess potential clinical impacts.
According to the company’s statement, users of legitimate Dexcom G7 sensors should continue their prescribed monitoring regimens while verifying device authenticity with their healthcare providers. The CDC’s diabetes management guidelines emphasize the importance of reliable glucose monitoring for optimal patient outcomes.
Quality and accounting reviews identified theft of G7 sensor lots designated as manufacturing scrap and intended for destruction
— DexCom, Inc. (FDA Safety Alert, May 2026)
What this means
Frequently asked questions
How can patients verify their G7 sensors are legitimate?
Contact your healthcare provider or Dexcom customer service to verify device lot numbers and authenticity. Legitimate sensors will have proper packaging and documentation from authorized distributors.
What risks do stolen defective sensors pose?
Manufacturing rejects may provide inaccurate glucose readings, potentially leading to inappropriate treatment decisions. These devices were rejected for failing quality standards and pose safety risks.
Should current G7 users be concerned?
Users of properly sourced G7 sensors from legitimate channels should continue normal use while verifying device authenticity with their healthcare provider if concerned.
The investigation into the Dexcom G7 sensor theft underscores the critical importance of secure medical device disposal and supply chain integrity. As healthcare systems increasingly rely on sophisticated monitoring technologies, robust protocols for handling rejected products become essential for maintaining patient safety and preventing potentially dangerous devices from reaching clinical use.
Source: Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
Was this article helpful?
Related Coverage
